COMPUS Communiqué — Vol. 5, No. 3

June 4, 2009

In This Issue

CADTH Releases Two New Reports on Blood Glucose Test Strips

The Canadian Agency for Drugs and Technologies in Health (CADTH) has released the following two Optimal Therapy Reports from its blood glucose test strips topic:

CADTH thanks all stakeholders who provided comments during the feedback period for these documents. The final reports provide the detailed clinical and economic evidence used in the development of CADTH’s Optimal Therapy Recommendations for the Prescribing and Use of Blood Glucose Test Strips.

Invitation to Provide Additional Studies for the Type 2 Diabetes Topic

CADTH is currently working to identify optimal second-line therapies for patients with type 2 diabetes after the failure of metformin monotherapy.

 

A list of randomized controlled trials that will be included in the systematic review for this project is now available online. The list does not include conference abstracts that are not indexed in databases such as MEDLINE, PubMed, or EMBASE. These databases were searched separately, and the selection process is ongoing.

CADTH invites all interested parties to suggest additional studies evaluating the efficacy and safety of second-line therapies for patients with type 2 diabetes after metformin monotherapy has failed that have not been included in our list. Please forward your suggestions to compusfeedback@cadth.ca by Thursday, June 18, 2009.

 

Visit the CADTH website for more information about the type 2 diabetes topic.

New for Pharmacists: Accredited Presentations on Insulin Analogues Now Available

CADTH is proud to announce that the Canadian Council on Continuing Education in Pharmacy has now accredited its continuing education presentations for pharmacists (originally released on March 30, 2009). The updated presentations are designed for use in education sessions regarding the optimal prescribing and use of insulin analogues. For more information about these presentations, or if you are a continuing education coordinator and would like to arrange a presentation in your area, contact the Liaison Officer in your jurisdiction.

New for Physicians: Accredited Presentations on Insulin Analogues Now Available

Two new presentations for physicians, designed for use in education sessions regarding the optimal prescribing and use of insulin analogues, are available online. The didactic presentation is accredited for up to 1.0 MAINPRO-M1 and MOC Section 1 study credits, and the interactive workshop is accredited for up to 2.0 MAINPRO-C study credits, 2.0 MAINPRO-M1, and 2.0 Section 1 study credits (valid until April 15, 2010). For more information about these presentations, or if you are a continuing medical education coordinator and would like to arrange a presentation in your area, contact the Liaison Officer in your jurisdiction.

Reminder: Webinar on Insulin Analogues on June 18 or 23, 2009

Don’t miss the upcoming Continuing Medical Education webinar examining the use of insulin analogues for the treatment of diabetes. CADTH is presenting this program in partnership with the University of British Columbia’s Division of Continuing Professional Development. The College of Family Physicians of Canada has approved this interactive webinar for up to 1.0 MAINPRO-M1 and MOC Section 1 study credits.

Dr. Marshall Dahl, a leading endocrinologist, will review the evidence supporting the use of human insulin and insulin analogues in the treatment of diabetes. This session will also identify the optimal use of insulin preparations for diabetes in the general population and with special cases where insulin analogues should be considered.

Insulin Preparations ─ Which Types for Which Patients?

Thursday, June 18, 2009 from 7:00 p.m. to 8:00 p.m. EDT

or

Tuesday, June 23, 2009 from 11:00 a.m. to 12:00 p.m. EDT

Space is limited ─ register now!

Evidence-based Optimal Therapy Reports and intervention tools are also available to support the optimal prescribing and use of insulin analogues.

CADTH Employment Opportunities

CADTH is seeking candidates for a variety of positions that are posted on the Careers page.

Feedback

We welcome your feedback. Tell us what you think of the COMPUS Communiqué.